The battle begins One big thing standing in the way of Regeneron and Sanofi turning Praluent into a success is another biotech giant. Amgen won approval for and launched its own PCSK9 inhibitor -- called Repatha -- in 2015, and the companies have been duking it out behind closed doors to position themselves to grab as much market share as they possibly can.